CVS Health Co. (NYSE:CVS) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in CVS Health Co. (NYSE:CVS) by 25.2% during the 3rd quarter, Holdings Channel reports. The firm owned 846,208 shares of the pharmacy operator’s stock after buying an additional 170,566 shares during the quarter. Natixis Advisors LLC’s holdings in CVS Health were worth $53,210,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. TIAA Trust National Association increased its stake in shares of CVS Health by 0.9% during the first quarter. TIAA Trust National Association now owns 40,844 shares of the pharmacy operator’s stock worth $3,258,000 after purchasing an additional 369 shares in the last quarter. Resurgent Financial Advisors LLC raised its holdings in shares of CVS Health by 45.3% during the first quarter. Resurgent Financial Advisors LLC now owns 4,339 shares of the pharmacy operator’s stock valued at $346,000 after acquiring an additional 1,352 shares during the last quarter. Davis R M Inc. lifted its position in shares of CVS Health by 8.7% in the first quarter. Davis R M Inc. now owns 3,010 shares of the pharmacy operator’s stock valued at $240,000 after acquiring an additional 242 shares in the last quarter. Trustmark National Bank Trust Department boosted its stake in shares of CVS Health by 581.0% in the first quarter. Trustmark National Bank Trust Department now owns 24,047 shares of the pharmacy operator’s stock worth $1,918,000 after acquiring an additional 20,516 shares during the last quarter. Finally, Bahl & Gaynor Inc. raised its stake in CVS Health by 11.9% in the 1st quarter. Bahl & Gaynor Inc. now owns 15,833 shares of the pharmacy operator’s stock valued at $1,263,000 after purchasing an additional 1,680 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Down 3.4 %

NYSE CVS opened at $53.19 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. The firm has a market cap of $66.93 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.92 and a beta of 0.55. The firm has a 50 day simple moving average of $59.23 and a 200-day simple moving average of $58.66. CVS Health Co. has a one year low of $52.71 and a one year high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. The business had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.21 earnings per share. Equities research analysts anticipate that CVS Health Co. will post 5.48 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 5.00%. The ex-dividend date was Monday, October 21st. CVS Health’s payout ratio is presently 67.51%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Evercore ISI upped their target price on shares of CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Mizuho cut their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Wells Fargo & Company lowered their target price on CVS Health from $61.00 to $60.00 and set an “equal weight” rating on the stock in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a report on Friday, August 9th. Finally, Barclays lowered their price objective on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.